NCT03997929

Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)

Prospective Evaluation of 1.3-ß-D-glucan in the Peritoneal Fluid for the Diagnosis of Fungal Peritonitis in Critically Ill Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Central Hospital, Nancy, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

New rapid diagnostic strategies are warranted in intra-abdominal candidiasis (IAC). A previous retrospective study showed that one measure, the day of the surgery, of peritoneal 1.3-Beta-D-Glucan ≤ 310pg/ml could rule out an IAC. This strategy was independent of the patient underlying conditions and Candida risk factors. This study aimed to confirm these results with a multicenter prospective study

Conditions

• Intra Abdominal Infections
• Candidiasis, Invasive
• Peritoneal Candidiasis
• Critically Ill

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	1.3 BETA D GLUCAN	dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)

Timeline

• Start date: 2020-01-20
• Primary completion: 2022-12-31
• Completion: 2023-02-07
• First posted: 2019-06-25
• Last updated: 2023-02-09

Locations

4 sites across 1 country: France

Regulatory

• FDA-regulated device study